Macro­Gen­ics touts a PhI­II win in a head-to-head with best-sell­er Her­ceptin — shares rock­et high­er

Macro­Gen­ics $MGNX has claimed suc­cess in their Phase III tri­al of their drug mar­ge­tux­imab for metasta­t­ic breast can­cer, putting them on the path to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA